HGF and neoplasm: SRI 31215 inhibited the activation of the tumor-associated fibroblast, pro-HGF, the inactive precursor of HGF in colon cancer cells, blocked the crosstalk between DU145 colon cancer cells and tumor-associated fibroblasts, prevented fibroblast-dependent EMT and migration of cancer cells, and overcame fibroblast-induced resistance to cetuximab and gefitinib in HGF-producing RKO colon cancer cells (Owusu et al., 2016).